25 June 2022
: Case report 
Necrotizing Fasciitis In A Patient with Metastatic Clear Cell Ovarian Carcinoma Treated with Bevacizumab
Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Unexpected drug reaction
Asim Haider1ABCDEF*, Hitesh Gurjar1DEF, Haider Ghazanfar1DEF, Sridhar Chilimuri1ABCDEFDOI: 10.12659/AJCR.935584
Am J Case Rep 2022; 23:e935584
Table 1. Summary of laboratory findings.
| Parameter | Value | Reference range |
|---|---|---|
| Hemoglobin (g/dL) | 10.9 | 12.0–16.0 |
| White blood cell count (×10 μL) | 15.0 | 4.8–10.8 |
| Platelet (×10 μL) | 167.0 | 150–400 |
| Sodium, serum (mEq/L) | 134.0 | 135–145 |
| Potassium, serum (mEq/L) | 3.7 | 3.5–5.0 |
| Blood urea nitrogen, serum (mg/L) | 16.0 | 6.0–20.0 |
| Creatinine, serum (mg/dL) | 0.7 | 0.5–1.5 |
| C reactive protein, serum (mg/L) | 343.0 | <5.0 |
| Lactic acid (mmol/L) | 2.2 | 0.5–1.6 |
| Blood glucose level, serum (mg/dL) | 93.0 | 70–120 |
| Hemoglobin A1c (%) | 6.5 | 4.7–6.4 |